Fluoxetine and Serotonin syndrome: is the FAERS signal real?
Fluoxetine ↔ Serotonin syndrome
Fluoxetine, a selective serotonin-reuptake inhibitor, raises synaptic serotonin; excess serotonergic activity produces serotonin syndrome — agitation, clonus, hyperthermia, autonomic instability — most often when an SSRI is combined with another serotonergic drug (MAOIs, tramadol, triptans, linezolid). In this dataset serotonin syndrome carries 1,720 co-reports (PRR 31.2). Fluoxetine's long half-life makes the effect linger after the drug is stopped, and MAOI combinations are contraindicated.
Regulatory basis: fluoxetine prescribing information — serotonin syndrome; contraindicated with MAOIs.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset within hours to days of serotonergic load |
| Strength | met | PRR 31.2, large |
| Consistency | met | Reproduced across serotonergic drugs |
| Specificity | partial | Not specific to one drug within the class |
| Biological gradient | met | Worse with higher combined serotonergic load |
| Plausibility | met | Excess-serotonin mechanism |
| Coherence | met | Fits SSRI pharmacology |
| Experiment | met | Case series and dechallenge support it |
| Analogy | met | Analogous to other SSRI/MAOI combinations |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.